Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

9.0K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
9.0K
Combination Therapies and Personalized Medicine02:50

Combination Therapies and Personalized Medicine

6.3K
Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
6.3K
Treatment Resistant Cancers02:56

Treatment Resistant Cancers

3.8K
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.8K
Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase01:11

Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase

56
Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...
56
Pharmacogenomics: Identification of New Drug Targets01:29

Pharmacogenomics: Identification of New Drug Targets

55
Advances in genomics have profoundly influenced drug discovery by increasing both the speed and accuracy of pharmaceutical development. Pharmacogenomics, which examines how genetic variation influences drug response, facilitates the identification of novel therapeutic targets and enables patient stratification for personalized treatment. These strategies contribute to improved drug efficacy, minimized adverse effects, and more efficient clinical trial design.Mapping genetic differences...
55
Tumor Immunotherapy01:27

Tumor Immunotherapy

2.1K
Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
2.1K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Enhancing Outcome Measurement in Oncology Clinical Trials Through Artificial Intelligence: A Scoping Review.

JCO clinical cancer informatics·2026
Same author

Time to Treatment Failure as an End Point in Pragmatic Oncology Trials: Association With Progression-Free Survival Across Randomized Studies.

JCO precision oncology·2026
Same author

A Response to the Letter to the Editor.

Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer·2026
Same author

AI-Based Pathology classifier Predicts Sensitivity to Enzalutamide in Metastatic Hormone-Sensitive Prostate Cancer: A Biomarker Analysis of the ENZAMET Trial.

Clinical cancer research : an official journal of the American Association for Cancer Research·2026
Same author

Pembrolizumab and Denosumab in Clear-Cell Renal-Cell Carcinoma.

Clinical genitourinary cancer·2026
Same author

Time-to-progression ratio as a potential study endpoint in early-phase oncology trials: pooled analysis of phase II trials from the Australian MoST program.

Future oncology (London, England)·2026

Related Experiment Video

Updated: Mar 6, 2026

Testing Targeted Therapies in Cancer using Structural DNA Alteration Analysis and Patient-Derived Xenografts
10:27

Testing Targeted Therapies in Cancer using Structural DNA Alteration Analysis and Patient-Derived Xenografts

Published on: July 25, 2020

8.0K

Genomic Therapy Matching in Rare and Refractory Cancers.

Frank P Lin1,2,3, Subotheni Thavaneswaran1,2,3,4, John P Grady2,3

  • 1NHMRC Clinical Trials Centre, University of Sydney, Camperdown, New South Wales, Australia.

JAMA Oncology
|March 5, 2026
PubMed
Summary

Matching therapies to genomic biomarkers improved survival in advanced solid tumors, but only when supported by prospective clinical trial evidence. This highlights the importance of an evidence-based framework for precision oncology treatments.

More Related Videos

Author Spotlight: Finding New Therapeutic Targets for Malignant Peripheral Nerve Sheath Tumor Through Genome-Scale shRNA Screens
09:33

Author Spotlight: Finding New Therapeutic Targets for Malignant Peripheral Nerve Sheath Tumor Through Genome-Scale shRNA Screens

Published on: August 25, 2023

1.8K
Defining Gene Functions in Tumorigenesis by Ex vivo Ablation of Floxed Alleles in Malignant Peripheral Nerve Sheath Tumor Cells
09:37

Defining Gene Functions in Tumorigenesis by Ex vivo Ablation of Floxed Alleles in Malignant Peripheral Nerve Sheath Tumor Cells

Published on: August 25, 2021

2.2K

Related Experiment Videos

Last Updated: Mar 6, 2026

Testing Targeted Therapies in Cancer using Structural DNA Alteration Analysis and Patient-Derived Xenografts
10:27

Testing Targeted Therapies in Cancer using Structural DNA Alteration Analysis and Patient-Derived Xenografts

Published on: July 25, 2020

8.0K
Author Spotlight: Finding New Therapeutic Targets for Malignant Peripheral Nerve Sheath Tumor Through Genome-Scale shRNA Screens
09:33

Author Spotlight: Finding New Therapeutic Targets for Malignant Peripheral Nerve Sheath Tumor Through Genome-Scale shRNA Screens

Published on: August 25, 2023

1.8K
Defining Gene Functions in Tumorigenesis by Ex vivo Ablation of Floxed Alleles in Malignant Peripheral Nerve Sheath Tumor Cells
09:37

Defining Gene Functions in Tumorigenesis by Ex vivo Ablation of Floxed Alleles in Malignant Peripheral Nerve Sheath Tumor Cells

Published on: August 25, 2021

2.2K

Area of Science:

  • Oncology
  • Genomics
  • Clinical Trials

Background:

  • The clinical utility of matching therapies to genomic biomarkers with varying evidence levels is uncertain for rare and refractory cancers.
  • Precision oncology aims to tailor treatments based on individual molecular profiles.

Purpose of the Study:

  • To assess if a tiered, evidence-based framework for matching genomic biomarkers to therapies correlates with overall survival in advanced solid tumors.
  • To evaluate the impact of different levels of evidence supporting biomarker-therapy associations on patient outcomes.

Main Methods:

  • A multicenter cohort study within Australia's nationwide precision oncology program.
  • Systemic therapy selection based on comprehensive genomic profiling and the TOPOGRAPH knowledge base, stratifying biomarker-drug pairs by evidence tiers (1-3A for prospective trials, 3B/4 for investigational/repurposed).
  • Overall survival analyzed using time-dependent multivariable Cox proportional hazards models.

Main Results:

  • Among 3383 patients, 1270 had clinically active biomarkers (tiers 1-3A).
  • Patients receiving matched therapy (tiers 1-3A) showed significantly longer median overall survival (21.2 months) compared to unmatched therapy (12.8 months; aHR, 0.60; P=.001).
  • No survival benefit was observed for therapies matched to investigational evidence (tiers 3B/4) or repurposed therapies lacking direct evidence (tier 3B).

Conclusions:

  • Matching therapies to genomic biomarkers improves survival in advanced solid tumors exclusively when supported by prospective clinical trial evidence.
  • An evidence-based framework is crucial for prioritizing genomically guided therapies in precision oncology.
  • The findings underscore the need for robust evidence to guide biomarker-directed treatment selection.